Featured
Exhibitors

Safety Net Hospitals for Pharmaceutical Access

Rx Job Solutions
Agenda

View/Download the Full Agenda

View/Download the Agenda at a Glance
 
As February approaches, the federal health care and 340B reform battles are drawing closer to an end. The 340B Coalition’s 2010 Winter Conference in San Francisco will present a perfect opportunity to examine where safety net providers go next, at the federal level and in the states, to expand access to low-cost pharmaceuticals and ensure compliance during a time of increased enforcement.  It is also the ideal forum for other 340B stakeholders-including pharmaceutical manufacturers, wholesalers, retail pharmacies, and state and local government agencies to assess the impact of this landmark effort to overhaul our health care system.

The Winter Conference will cover the following areas of focus:
  • 340B Reform:  How Will It Impact 340B Stakeholders?
    • The inside story:  What were the key issues and interests that shaped the 340B reform legislation?
    • Why did 340B reform pass or fail?
    • What will happen now?  How and when is the Administration expected to implement the 340B reforms?
    • If the legislation does not pass, what happens in 2010?
    • What are the immediate benefits, and for whom?
    • What potential hurdles remain to implementation?
    • What compliance challenges face 340B entities and pharmaceutical manufacturers?
  • Federal Health Care Reform:  Winners and Losers
    • What really happened with health care reform legislation?
    • What will happen now?  How is the Administration expected to implement health care reforms?
    • What are the major implications of health care reform for 340B providers and industry?
    • What is the schedule for implementation of the reforms?
    • What are the next battles? Will the Administration try again to achieve reforms not enacted?
  • Health Care Reform at the Local Level
    • Are state and local health care reform efforts succeeding in providing greater access for vulnerable populations to low-cost pharmaceuticals?
    • How are state and local reform efforts impacting 340B providers? 
    • Can state and local health care reform efforts, such as Healthy San Francisco, serve as models for other jurisdictions seeking to expand access to low-cost pharmaceuticals?
  • New Kids on the Block: Children’s Hospitals   
    • What are the details of the final guidelines and the status of implementation?
    • Learn about success stories in implementation
    • How have children’s hospitals been meeting conditions for enrollment, including the use of an independent auditor to certify DSH percentages?
    • How is the pharmaceutical industry reacting to the new player in the market?
    • What barriers are children’s hospitals facing in joining the 340B program?
    • How successful have children’s hospitals been in obtaining retroactive discounts?
  • Trends and Developments in Medicaid & Medicare Billing
    • Who Gets the 340B Discount?:   Balancing the needs of safety net providers and state Medicaid programs
    • Update on the HHS Inspector General’s studies of Medicaid and Medicare Part B reimbursement and the implications of those findings for 340B providers and industry
    • CA Medicaid carve-out prohibition: A cautionary tale
    • Update on expansion of the Medicaid rebate program to physician-administered drugs: SNHPA litigation and state implementation
  • Multiple Contract Pharmacies
    • What is the status of publication and implementation of the final multiple contract pharmacy guidelines?
    • What is permitted under the final guidelines and what is not permitted?
    • What will be the role of pharmacy benefit managers (PBMs) under the multiple contract pharmacy guidelines?
    • Multiple contract pharmacy success stories under the Alternative Method Demonstration Projects (AMDPs)
    • What is the future of “network model” AMDPs?
  • Pricing Changes Under Health Care Reform & Their Implications for 340B
    • Average Manufacturer Price (AMP) redefined under Medicaid legislation
    • Increase in minimum rebate percentage under Medicaid
    • Expansion of the Medicaid rebate program to managed care drugs:  340B held harmless?
    • Litigation redefining Average Wholesaler Price (AWP)

Continuing Education Credits for Pharmacists Available!

Comprehensive Pharmacy Services Continuing education credits for pharmacists will be made available for this conference.

Accreditation Council for Pharmacy Education (ACPE) continuing education credits provided by Comprehensive Pharmacy Services.

   © Copyright 2010 Safety Net Hospitals for Pharmaceutical Access
Top of Page